Quick search:
| Result | Content | Outlet | Published | Research |
|---|---|---|---|---|
| Result | Content | Outlet | Published | Research |
| 1 | Detrimental Effect of Quantity of Smoking on Survival in PF-ILD Patients | Physician's Weekly | 1 day ago | |
| 2 | Conventional VATS Biopsy Versus Awake VATS Biopsy in Fibrosing ILD | Physician's Weekly | 1 day ago | |
| 3 | Ofev for PF-ILD Now Reimbursed in 7 regions of Canada | Pulmonary Fibrosis News | 4 days ago | |
| 4 | Inhaled Prostacyclin Therapy for PH-ILD Patients (WHO Group 3) | Physician's Weekly | 1 day ago | |
| 5 | Cough-specific quality of life may predict disease progression in ILD | Healio | 6 days ago | |
| 6 | ATS issues new clinical practice guideline on IPF, progressive fibrotic ILDs | Healio | 22 hours ago | |
| 7 | Pulmonary Fibrosis Foundation Research Explores Quality and Access to Patient Care | Newswise | 1 day ago | |
| 8 | Cough-Specific QOL Linked to Poor Outcomes in ILD Patients | Medscape | 29 days ago | |
| 9 | Factors Linked to Poor Prognosis of RA-Associated Interstitial Lung Disease Determined | Rheumatology Advisor | 8 days ago | |
| 10 | Global Pulmonary Hypertension Associated with Interstitial Lung Disease Market Report 2022 | Insight, Epidemiology and Forecasts to 2032 | 4 days ago | |
| 11 | 49-year-old man gets new lease of life after bilateral lung transplant 49-year-old man gets new lease of life after bilateral lung transplant | The New Indian Express | 2 days ago | |
| 12 | CHEST and Three Lakes Foundation collaborate to reduce delays in diagnosing Interstitial Lung Diseases | News-Medical.Net | 29 days ago | |
| 13 | Boehringer Ingelheim Canada announces reimbursement for OFEV® (nintedanib) in seven public drug plans for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD) | Canada NewsWire | 15 days ago | |
| 14 | Influence of Obesity Associated With Anti-Aminoacyl-tRNA Synthetase Antibodies | Physician's Weekly | 5 days ago | |
| 15 | A Closer Look at Anti-tRNA Synthetase Syndrome in ILD | Physician's Weekly | 2 months ago | |
| 16 | New Clinical Practice Guidelines on Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis | Newswise | 14 days ago | |
| 17 | Prometheus Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress | GlobeNewswire | 5 days ago | |
| 18 | Treatment options expanding for progressive fibrosing ILD | Healio | 6 months ago | |
| 19 | Contemporary Concise Review 2021: Interstitial lung disease | DocWire News | 13 days ago | |
| 20 | Sjögren's syndrome 'not curable, but certainly treatable' with available therapies | Healio | 3 days ago | |
| 21 | ILD year in review: Benefits of newer therapies, effects of air pollution, risk factors | Healio | 4 months ago | |
| 22 | Pulmonary Fibrosis Foundation Expands Clinical Trial Resources for Patients | Newswise | 7 hours ago | |
| 23 | Interstitial lung disease 2021 | The Lancet | 8 months ago | |
| 24 | Interstitial Lung Disease in Patients with Primary Sjögren's Syndrome | Pulmonology Advisor | 1 month ago | |
| 25 | Computed Tomography of the Chest to Screen for Interstitial Lung Disease in Patients With Systemic Sclerosis at Expert Scleroderma Centers in the United States | DocWire News | 25 days ago | |
| 26 | Alejandra Garcia-Wagner Obituary (1981 | 2022) | 17 days ago | |
| 27 | aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis | Antibodies | News Channels | PipelineReview.com | 1 day ago | |
| 28 | Identifying ILD: Symptomology and Work-Up | OncLive | 8 months ago | |
| 29 | Nine Organizations Team Up to Present First ILD Day on September 15 to Drive Awareness of Interstitial Lung Disease | PR Newswire | 9 months ago | |
| 30 | Asia Pacific Idiopathic Pulmonary Fibrosis Industry to 2027 | by Drug Type, Distribution Channel and Country | 11 hours ago | |
| 31 | Optimizing the Management of ILD: Take-Home Messages | OncLive | 7 months ago | |
| 32 | Nintedanib Found to Slow Progression of Fibrosing Interstitial Lung Disease | Rheumatology Advisor | 6 months ago | |
| 33 | What Are the Risk Factors for ILD? | WebMD | 1 year ago | |
| 34 | Longer travel distance to subspecialty ILD clinic tied to worse clinical outcomes | Healio | 4 months ago | |
| 35 | Nintedanib slows FVC decline in autoimmune-related interstitial lung disease | Healio | 3 months ago | |
| 36 | Rheumatoid arthritis-ILD mortality remains stable despite fewer arthritis-related deaths | Healio | 5 months ago | |
| 37 | Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test's Clinical Performance and Utility in Lung Cancer Risk Assessment | Business Wire | 1 day ago | |
| 38 | Inversago Pharma Appoints Glenn S. Vraniak as Chief Financial Officer | Maryville Daily Times | 14 hours ago | |
| 39 | Sex and Gender in Asthma, COPD, OSA, ILD, and Lung Cancer | Pulmonology Advisor | 1 month ago | |
| 40 | The Prevalence of Pulmonary Embolism in Patients With Interstitial Lung Disease: A Cross-Sectional Retrospective Study | Cureus | 2 months ago | |
| 41 | Changes in Nailfold Video capillaroscopy Are Linked to the Presence and Severity of Systemic Sclerosis–Related Interstitial Lung Disease | Physician's Weekly | 5 months ago | |
| 42 | UK Study Explores Prevalence of Post-COVID Interstitial Lung Disease | Pulmonology Advisor | 7 months ago | |
| 43 | Respiratory | interstitial lung disease | 6 months ago | |
| 44 | What's the Evidence Base for Prescribing New SSc-ILD Drugs? | Medscape | 2 months ago | |
| 45 | Treatment outcomes of patients with stage III non-small cell lung cancer and interstitial lung diseases receiving intensity-modulated radiation therapy: A single-center experience of 85 cases | DocWire News | 26 days ago | |
| 46 | Trends in Incidence, Outcomes of RA-Associated Interstitial Lung Disease Assessed | Rheumatology Advisor | 3 months ago | |
| 47 | Low BMI, weight loss associated with increased mortality in patients with fibrotic ILD | Healio | 6 months ago | |
| 48 | Nintedanib has greater impact on SSc-ILD in patients without cough, dyspnea at baseline | Healio | 2 months ago | |
| 49 | Malignancy Risk of Mycophenolate Mofetil and Azathioprine in Fibrotic ILD | Pulmonology Advisor | 4 months ago | |
| 50 | Air pollution has various effects in fibrotic ILD | Healio | 5 months ago | |
| 51 | The Spectrum of Progressive Fibrosing Interstitial Lung Disease: Clinical and Managed Care Considerations | AJMC.com Managed Markets Network | 12 months ago | |
| 52 | ILD Progression, Not Diagnosis, Triggers Palliative Care | Medscape | 1 month ago | |
| 53 | Ofev: Side effects, cost, how it works, and more | Medical News Today | 29 days ago | |
| 54 | Chest CT-based Assessment of 1-year Outcomes after Moderate COVID-19 Pneumonia | RSNA Publications Online | 7 days ago | |
| 55 | Quantity of smoking tied to reduced survival in patients with progressive fibrosing ILD | Healio | 3 months ago | |
| 56 | Lassen Therapeutics Presents Data Demonstrating Preclinical Anti-fibrotic Effect of LASN01, a Novel IL-11 Receptor-Blocking Antibody, at the American Thoracic Society 2022 Annual Meeting | Yahoo Finance | 8 hours ago | |
| 57 | Janus kinase inhibitors for the management of ILD | DDDT | Dove Medical Press | 2 months ago | |
| 58 | Long-term Mortality Decline in RA Skips Those Who Also Have Interstitial Lung Disease | AJMC.com Managed Markets Network | 5 months ago | |
| 59 | Low BMI, Weight Loss Predict Mortality Risk in ILD | Medscape | 4 months ago | |
| 60 | Review Examines Interstitial Lung Disease in Lysosomal Storage Disorders | AJMC.com Managed Markets Network | 6 months ago | |
| 61 | NICE approves Ofev for PF-ILD | PharmaTimes | 7 months ago | |
| 62 | Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine | Cureus | 3 months ago | |
| 63 | Can BMI and Weight Loss Predict Mortality in Fibrotic Interstitial Lung Disease? | Pulmonology Advisor | 6 months ago | |
| 64 | ILD Screening in Rheumatic Diseases: Strategies to Consider | Medscape | 4 months ago | |
| 65 | Optimizing the Management of ILD: Steroids, Therapy Cessation, and Dose Modification | OncLive | 7 months ago | |
| 66 | Childhood Interstitial Lung Disease in an Immunocompetent Patient Without Exposure | Cureus | 3 months ago | |
| 67 | Rheumatoid arthritis-ILD associated with excess mortality | Healio | 10 months ago | |
| 68 | Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) | BioSpace | 2 months ago | |
| 69 | Boehringer Ingelheim's pulmonary fibrosis treatment produces promising phase 2 data | PMLiVE | 8 hours ago | |
| 70 | Lung Function Decline Linked to Increased Risk for Hospitalization in Patients With SSc-ILD | Rheumatology Advisor | 4 months ago | |
| 71 | MMP-7 as Biomarker for Scleroderma-Associated Interstitial Lung Disease | Pulmonology Advisor | 4 months ago | |
| 72 | The legacy of uranium mining on Navajo lands | WBUR News | 7 days ago | |
| 73 | T-DXd for HER2+ MBC and Interstitial Lung Disease | OncLive | 6 months ago | |
| 74 | ECMO consideration recommended for myositis-associated rapidly progressive ILD | Healio | 9 months ago | |
| 75 | ICIs for NSCLC: Patients With ILD Show Greater Risk | Medscape | 4 months ago | |
| 76 | Protara Therapeutics (NASDAQ:TARA) and aTyr Pharma (NASDAQ:LIFE) Head to Head Review | Defense World | 2 days ago | |
| 77 | Interstitial Lung Disease (ILD): Overview and More | Verywell Health | 2 years ago | |
| 78 | Ofev Seen to Slow Lung Function Decline Across SSc-ILD Subgroups | Scleroderma News | 7 months ago | |
| 79 | Nasal high-flow oxygen therapy yields benefit in severe ILD | Healio | 10 months ago | |
| 80 | 9 Types of Interstitial Lung Disease | Pulmonary Fibrosis News | 5 years ago | |
| 81 | Immunosuppressants remain 'cornerstone' therapy for CTD-ILD as drug options emerge | Healio | 9 months ago | |
| 82 | Identifying Interstitial Lung Disease | Curetoday.com | 11 months ago | |
| 83 | Waves Ships Nx Virtual Studio Collection | Sonic State | 10 hours ago | |
| 84 | Phase 2 Trial of PRA023 in SSc-ILD Patients Planned for Next Year | Scleroderma News | 5 months ago | |
| 85 | Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial | GlobeNewswire | 5 months ago | |
| 86 | Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) | BioSpace | 5 months ago | |
| 87 | Jesse Roman, MD, on New Interstitial Lung Disease Primers | Consultant360 | 4 months ago | |
| 88 | Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis | The Lancet | 4 months ago | |
| 89 | FDA Approves First Treatment for Group of Progressive Interstitial Lung Diseases | FDA | FDA.gov | 2 years ago | |
| 90 | Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccination | Thorax (BMJ) | 5 months ago | |
| 91 | Higher CTRP9 linked to worse pulmonary function in SSc-related interstitial lung disease | Healio | 10 months ago | |
| 92 | Pulmonary Rehab for Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis | Pulmonology Advisor | 6 months ago | |
| 93 | Blood Levels of KL-6 Protein May Detect Interstitial Lung Disease | ANCA Vasculitis News | 3 months ago | |
| 94 | First-line nintedanib feasible for SSc-ILD with extrapulmonary disease, progression risk | Healio | 10 months ago | |
| 95 | Exercise Training for Interstitial Lung Disease | Physician's Weekly | 4 years ago | |
| 96 | Global Interstitial Lung Disease Market to Surpass US$ 2453.5 Million by 2028, Says Coherent Market Insights (CMI) | GlobeNewswire | 5 months ago | |
| 97 | ILD year in review: New guidelines, FDA approvals and more | Healio | 1 year ago | |
| 98 | Concomitant medication burden linked with antifibrotic medication intolerance in IPF | Healio | 4 months ago | |
| 99 | Role of Bronchoscopy in Identifying and Managing ILD | OncLive | 7 months ago | |
| 100 | Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update | Yahoo Finance | 5 days ago |